Warner Chilcott PLC (WCRX): Today's Featured Health Care Loser

Warner Chilcott ( WCRX) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.3%. By the end of trading, Warner Chilcott fell 32 cents (-1.6%) to $20.12 on average volume. Throughout the day, 2.8 million shares of Warner Chilcott exchanged hands as compared to its average daily volume of 3.2 million shares. The stock ranged in price between $19.92-$20.51 after having opened the day at $20.44 as compared to the previous trading day's close of $20.44. Other company's within the Health Care sector that declined today were: MediciNova ( MNOV), down 42.9%, Catalyst Pharmaceutical Partners ( CPRX), down 34.5%, Urologix ( ULGX), down 13.7%, and Senesco Technologies ( SNT), down 9.3%.

Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. Warner Chilcott has a market cap of $5.03 billion and is part of the drugs industry. The company has a P/E ratio of 13.3, below the average drugs industry P/E ratio of 16.6 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Warner Chilcott as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, compelling growth in net income, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated.

On the positive front, Vermillion ( VRML), up 47.9%, Rosetta Genomics ( ROSG), up 44.9%, Telik ( TELK), up 29.8%, and ARCA biopharma ( ABIO), up 27%, were all gainers within the health care sector with Bristol-Myers Squibb Company ( BMY) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).